HRT for Perimenopause: UK vs Australia Compared
Compare perimenopause HRT access, cost, formulary, specialist availability, and patient advocacy in the UK vs Australia. What women in each country need to know.
Two Countries, Very Different Starting Points
Both the United Kingdom and Australia have experienced a surge in public awareness around perimenopause and menopause care in recent years, driven in part by high-profile advocacy campaigns, media coverage, and growing patient demand. Despite this shared momentum, the two countries approach HRT prescribing from quite different systemic starting points. The UK operates under the NHS, where body-identical HRT preparations have been increasingly championed following the publication of updated NICE guidelines in 2015 and 2019, and where the Menopause Workplace Bill and high-profile advocates have driven significant policy attention. Australia operates under a PBS (Pharmaceutical Benefits Scheme) system where only certain HRT products attract government subsidy, and where the cultural openness to HRT has historically been more cautious than in the UK, partly as a legacy of the 2002 WHI study fears that depressed prescribing globally. Understanding these differences helps women in each country set realistic expectations about what they can access, at what cost, and through which channels.
Formulary Access: What Products Are Available in Each Country
In the UK, the body-identical HRT formulary is relatively broad. Transdermal oestradiol patches (Evorel, Estradot), gels (Oestrogel, Sandrena, Lenzetto spray), and vaginal preparations (Vagifem, Ovestin) are all available on NHS prescription. Utrogestan (micronised progesterone) is the recommended body-identical progestogen in the UK, listed in NICE guidelines and widely available. Testosterone cream (Androfeme) was approved by the MHRA in 2024, addressing a long-standing gap. In Australia, the PBS subsidises a narrower selection. Transdermal patches including Estradot and Climara are PBS-listed, and Prometrium (equivalent to Utrogestan) is available. However, oestrogen gels and sprays are more recently available in Australia and are not yet universally PBS-subsidised, meaning out-of-pocket costs can be higher. Testosterone for women in Australia has long been managed via compounding pharmacies using formulations not specifically licensed for female use, a workaround that is technically accessible but adds complexity. Access to the full range of body-identical options therefore favours UK women in terms of NHS formulary breadth.
Cost: NHS Prescription Charges vs Australian Out-of-Pocket Costs
In the UK, all HRT items prescribed on the NHS are available under the Prescription Prepayment Certificate (PPC) scheme. Women needing ongoing HRT prescriptions can purchase an annual PPC for approximately 32 pounds (2025 figure), covering all NHS prescriptions including HRT at a fixed cost regardless of how many items are needed. This represents extraordinary value for women managing multiple HRT components. Additionally, from April 2023, a dedicated menopause PPC specifically for HRT was introduced at a reduced cost, further reducing financial barriers. In Australia, PBS-subsidised medications are available at the concessional rate (around AUD 7.70 for concession card holders) or the general patient rate (around AUD 31.60 per item in 2025). Women needing multiple HRT products each month may pay per item, and those needing non-PBS products such as testosterone compounding or newer oestrogen gel formulations pay the full private price, which can amount to AUD 50 to 120 per month depending on the products. The UK system therefore offers more comprehensive cost protection through the PPC mechanism.
Specialist Availability and Wait Times
Access to a menopause specialist is challenging in both countries, but the nature of the challenge differs. In the UK, NHS menopause clinics exist but carry long waiting lists in many areas, sometimes exceeding six to twelve months. Many women choose private menopause clinics, which have proliferated significantly since around 2020, with consultation fees typically ranging from 150 to 350 pounds. The British Menopause Society (BMS) and Menopause Matters provide directories of accredited specialists. In Australia, the Australasian Menopause Society (AMS) maintains a similarly useful directory of specialists, but the geographic challenge is more acute: specialist menopause care is heavily concentrated in major cities (Sydney, Melbourne, Brisbane), and women in rural or regional areas face significant barriers to access. Telehealth has improved this situation since 2020. Both countries are also developing specialist menopause nurse practitioner and GP upskilling programmes, but the pace of capacity building remains insufficient relative to demand in both healthcare systems.
Prescribing Culture and GP Attitudes
UK prescribing culture around HRT shifted markedly between 2015 and 2023. Updated NICE guidance emphasising individualised risk assessment, the safety profile of transdermal oestradiol, and the legitimate role of body-identical HRT significantly changed the consensus position of GPs and practice nurses. High-profile media campaigns and patient advocates accelerated cultural change. Many UK GPs now feel confident initiating and managing standard HRT, though gaps remain, and women still report being dismissed or undertreated in some practices. In Australia, the AMS has similarly worked to update GP education, and attitudes have improved, but the legacy of extreme post-WHI caution is arguably more persistent in the Australian primary care culture. Some Australian GPs remain reluctant to prescribe without specialist input, and women frequently report needing to self-advocate more actively, bring their own research, and sometimes change GP to access appropriate care. The private women's health clinic sector in Australia serves women who can afford it, but cost is a more significant barrier to accessing knowledgeable practitioners in Australia than in the UK.
Patient Advocacy and What Women in Each Country Can Do
Both countries have active patient advocacy ecosystems. In the UK, Menopause Matters, the Menopause Charity, and Balance (Dr Louise Newson's platform) provide extensive information resources, clinician directories, and community support. The political profile of menopause has risen sharply, with parliamentary debates, workplace legislation, and media coverage making it a recognised health priority. In Australia, the Australasian Menopause Society and organisations including the Jean Hailes Foundation for Women's Health provide trusted clinical information. The podcast and online community space is active and growing. For women in either country who feel undertreated, practical strategies include: requesting an appointment with a GP who has a special interest in menopause, using the BMS or AMS specialist directories, asking for a referral to a gynaecologist or endocrinologist with menopause expertise, accessing telehealth menopause services, and arriving at appointments with a symptom diary and a list of specific questions. Both countries are moving in the right direction, but patient self-advocacy remains an unfortunately necessary skill in both systems.
Related reading
Get your personalized daily plan
Track symptoms, match workouts to your day type, and build a routine that adapts with you through every phase of perimenopause.